Home › Kidney Cancer (Renal Cell Carcinoma) › Massachusetts
Kidney Cancer (Renal Cell Carcinoma) clinical trials in Massachusetts
18 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Massachusetts General Hospital Cancer Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07227415Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Beverly Hospital, Beverly
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06661720A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07123090Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06966024A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07195682A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT03972657Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Lahey Hospital and Medical Center, Burlington
- Lahey Medical Center-Peabody, Peabody
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT07383441KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT06026410Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06053658Drug Screening Using Novel IMD in Renal Cell Carcinoma
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT05700461Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT07397611Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT04787042From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.